A prodrug strategy to deliver cisplatin(IV) and paclitaxel in nanomicelles to improve efficacy and tolerance

Xiao, Haihua; Song, Hang; Yang, Qiang; Cai, Haidong; Qi, Ruogu; Yan, Lesan; Liu, Shi; Zheng, Yonghui; Huang, Yubin; Liu, Tongjun; Jing, Xiabin

doi:10.1016/j.biomaterials.2012.05.049

Cited by 187 publications

(142 citation statements)

References 28 publications

Supporting

Mentioning

141

Contrasting

Order By: Relevance

“…For the free drugs and the drug-loaded NLC-treated groups, two conclusions could be summarized as follows: (1) the containing of RGD was more effective than the use of non-RGD contained TMZ/NLCs. (2) The TMZ-loaded NLCs showed better antitumor effect compared with free drug (Xiao et al, 2012;Lv et al, 2014). The NLCs formulation is good, and the modified NLCs formula is excellent.…”

Section: In Vivo Therapeutic Studiesmentioning

confidence: 94%

Novel RGD containing, temozolomide-loading nanostructured lipid carriers for glioblastoma multiforme chemotherapy

Song

Mao

et al. 2015

Drug Delivery

View full text Add to dashboard Cite

Context: Glioblastoma multiforme (GBM) is the most common malignant brain tumor originating in the central nervous system. Efficient delivery of therapeutic molecules to the cells and tissues is a difficult challenge. Objective: Arginine-glycine-aspartic acid peptide (RGD)-modified nanostructured lipid carriers (NLCs) were used for the delivery of temozolomide (TMZ) into the GBM to provide a new paradigm in gliomatosis cerebri treatment. Methods:RGD-conjugated polyethylene glycol-b-distearoylphosphatidylethanolamine (PEG-DSPE) was synthesized. RGD containing, TMZ-loaded NLCs (RGD-TMZ/NLCs) were prepared. Their particle size, zeta potential, drug encapsulation efficiency (EE) and drug release behavior were evaluated. In vitro cytotoxicity study of TMZ/NLCs was tested in U87 malignant glioma cells (U87MG cells). In vivo antitumor efficacy of the carriers was evaluated on mice bearing GBM model. Results: The U87MG cells were successfully inhibited by RGD-TMZ/NLCs in vitro. RGD-TMZ/NLCs also displayed the highest antitumor efficacy in vivo than all the other formulations used for comparison. Conclusion: RGD-TMZ/NLCs were efficient in selective delivery of TMZ into U87MG cells, and inhibition efficacy is high. These RGD-modified vectors could be a superior drug delivery nanosystem to achieve therapeutic efficacy, and this research could be a new promising strategy for treatment in malignant gliomatosis cerebri.

show abstract

Section: In Vivo Therapeutic Studiesmentioning

confidence: 94%

Novel RGD containing, temozolomide-loading nanostructured lipid carriers for glioblastoma multiforme chemotherapy

Song

Mao

et al. 2015

Drug Delivery

View full text Add to dashboard Cite

show abstract

“…On the right-hand-side of Equation (2) is the Padé approximant [20] of the model transfer function, is an estimator of the model parameter called a gain of a dynamic system, a 1 , … a n , b 1 , … b m are additional model parameters, and n is the highest degree of the nominator polynomial, and m is the highest degree of the denominator polynomial, where n<m [6][7][8][9][10][11][12][13][14][15][16].…”

Section: Methodsmentioning

confidence: 99%

Mathematical Models of the Pharmacokinetic Behavior of Digoxin in Five Healthy Subjects following Rapid Intravenous Injection of 1 mg of Digoxin

Äurišová¹

2015

J Develop Drugs

View full text Add to dashboard Cite

Keywords: Digoxin; Intravenous injection; Mathematical model IntroductionDigoxin is widely used in clinical practice for treatment of congestive heart failure (CHF) and atrial fibrillation (AF) or an acute coronary syndrome (ACS) [1][2][3][4]. Pharmacokinetics of digoxin was investigated in the previous study by Kramer et al. in five healthy male volunteers after a rapid intravenous injection of 1.0 mg of digoxin [1]. The current study is a companion piece of the previous study by Kramer et al. [1], therefore the data published in the previous study by Kramer et al. [1] are used, with the main objective to provide a further example which shows a successful use of an advanced mathematical modeling method based on the theory of dynamic systems in mathematical modeling in pharmacokinetics [5][6][7][8][9][10][11][12][13][14][15][16]. An additional objective was to motivate researchers working in the field of pharmacokinetics to use of an alternative modeling method, namely a modeling method based on the theory of dynamic systems in the development pharmacokinetic models. Previous examples presenting an advantageous use of the modeling method used in the current study can be found in the articles available online, which can be downloaded free of cost from the following web pages of the author: http://www.uef.sav.sk/durisova.htm and http://www.uef.sav.sk/advanced.htm. The current study continued to inform pharmacokinetic community about benefits linked to the use of computational tools from the theory of dynamic systems in mathematical modeling in pharmacokinetics. MethodsAs stated previously, an advanced mathematical modeling method based on the theory of dynamic systems was employed to develop mathematical models of the pharmacokinetic behavior of digoxin in the volunteers investigated in the previous study by Kramer et al. [1], and in the current study. The development of a mathematical model of the pharmacokinetic behavior of digoxin in each volunteer was performed in the following steps:In the first step of the model development process, a pharmacokinetic dynamic system, here denoted as H, was defined for the volunteer by relating the Laplace transform of volunteer's plasma concentration time profile of digoxin, here denoted as C(S), and the Laplace transform of the intravenous injection (input) of 1.0 mg of digoxin into the body of the volunteer, here denoted as I(S).The following simplifying assumptions were introduced prior the model development process: a) initial conditions of each pharmacokinetic dynamic system H were zero; b) pharmacokinetic processes occurring in the body after the intravenous injection of digoxin were linear and time-invariant; c) concentrations of digoxin were the same throughout all subsystems of the pharmacokinetic dynamic system H (where each subsystem was an integral part of the pharmacokinetic dynamic system H); d) no barriers to the distribution and/or elimination of digoxin existed.In the second step of the model development process, the pharmacokinetic dynamic system H, was used...

show abstract

“…They were used to mathematically describe static and dynamic properties of the pharmacokinetic behavior of acetaminophen [18][19][20] in the male Sprague-Daley rats investigated in the previous study by Bélander et al [1]. The modeling method used in the current study has been described in detail in the studies published previously [7][8][9][10][11][12][13][14][15][16], authored or co authored by the author of the current study.…”

Section: Venous Serum Concentration Of Acetaminophen (µG/ml)mentioning

confidence: 99%

“…In the second step, the pharmacokinetic dynamic system H was used to mathematically describe static and dynamic properties [18][19][20] of the pharmacokinetic behavior of acetaminophen in adult male Sprague-Dawley rats [1].…”

Section: Methodsmentioning

confidence: 99%

Untitled

2016

JAPLR

View full text Add to dashboard Cite

show abstract

A prodrug strategy to deliver cisplatin(IV) and paclitaxel in nanomicelles to improve efficacy and tolerance

Cited by 187 publications

References 28 publications

Novel RGD containing, temozolomide-loading nanostructured lipid carriers for glioblastoma multiforme chemotherapy

Novel RGD containing, temozolomide-loading nanostructured lipid carriers for glioblastoma multiforme chemotherapy

Mathematical Models of the Pharmacokinetic Behavior of Digoxin in Five Healthy Subjects following Rapid Intravenous Injection of 1 mg of Digoxin

Untitled

Contact Info

Product

Resources

About